» Articles » PMID: 29928910

Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-analysis of Observational and Clinical Studies

Overview
Specialty Dermatology
Date 2018 Jun 22
PMID 29928910
Citations 197
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with psoriasis have been reported.

Objectives: To assess the prevalence and incidence of PsA in patients with psoriasis.

Methods: Two authors independently searched 3 databases for studies reporting on the prevalence or incidence of PsA in patients with psoriasis. A proportion meta-analysis was performed to calculate the pooled proportion estimates of PsA in patients with psoriasis.

Results: A total of 266 studies examining 976,408 patients with psoriasis were included. Overall, the pooled proportion (95% confidence interval [CI]) of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%). In children and adolescents (<18 years of age), the pooled prevalence was 3.3% (95% CI, 2.1%-4.9%). The PsA prevalence was 22.7% (95% CI, 20.6%-25.0%) in European patients with psoriasis, 21.5% (95% CI, 15.4%-28.2%) in South American patients with psoriasis, 19.5% (95% CI, 17.1%-22.1%) in North American patients with psoriasis, 15.5% (95% CI, 0.009%-51.5%) in African patients with psoriasis, and 14.0% (95% CI, 95% CI, 11.7%-16.3%) in Asian patients with psoriasis. The prevalence of PsA was 23.8% (95% CI, 20.1%-27.6%) in studies in which the Classification Criteria for Psoriatic Arthritis were applied. The incidence of PsA among patients with psoriasis ranged from 0.27 to 2.7 per 100 person-years.

Limitations: Between-study heterogeneity may have affected the estimates.

Conclusions: We found that 1 in 4 patients with psoriasis have PsA. With the growing recognition of the Classification Criteria for Psoriatic Arthritis, more homogenous and comparable prevalence estimates are expected to be reported.

Citing Articles

Analysis of PEST Questionnaire Responses in Patients with Psoriasis in Daily Practice: Results from a Single-Center of Psoriasis in the Czech Republic.

Tivadar S, Hugo J, Fuzesiova K, Dolezal T, Turkova B, Gkalpakiotis S Dermatol Ther (Heidelb). 2025; .

PMID: 40032792 DOI: 10.1007/s13555-025-01374-6.


Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis.

Xie O, Wu M, Li A, Meng K, Xiang H, Tan C Clin Rheumatol. 2025; .

PMID: 39982592 DOI: 10.1007/s10067-025-07368-1.


IL-1 signaling enrichment in inflammatory skin disease loci with higher-risk allele frequencies in African ancestry.

Tsoi L, Dong Y, Patrick M, Sarkar M, Zhang H, Bogle R Res Sq. 2025; .

PMID: 39975900 PMC: 11838759. DOI: 10.21203/rs.3.rs-5724270/v1.


The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review.

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W Postepy Dermatol Alergol. 2025; 41(6):552-559.

PMID: 39877117 PMC: 11770571. DOI: 10.5114/ada.2024.143428.


Biomarkers of Extracellular Matrix Fragments in Patients with Psoriasis.

Johansen M, Holm Nielsen S, Port H, Todberg T, Lovendorf M, Skov L Int J Mol Sci. 2025; 26(1.

PMID: 39796116 PMC: 11720200. DOI: 10.3390/ijms26010261.